

Literaturverzeichnis

Die Ergebnisse dieser Arbeit wurden in folgender Publikation veröffentlicht:

Julia Kirchheiner, Mike Ufer, Ev-Charlott Walter et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. *Pharmacogenetics* 2004; **14**:19-26.

- A Aithal GP, Day CP, Kesteven PJJ et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet* 1999; **353**:717-719.

Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. *Chest* 2001; **119**:22S-38S.

Anzenbacher P, Anzenbacherova E. Cytochrome P450 and metabolism of xenobiotics. *Cell Mol Life Sci* 2001; **58**:737-747.

Aynacioglu A, Brockmöller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in Turkish population and functional relevance for phenytoin. *Br J Clin Pharmacol* 1999; **48**:409-415.

- B Bhasker CR, Miners JO, Coulter S et al. Allelic and functional variability of cytochrome 4502C9. *Pharmacogenetics* 1997; **7**:51-58.

Bloch A, Ben-Chetrit E, Muszkat M et al. Major bleeding caused by warfarin in a genetically susceptible patient. *Pharmacotherapy* 2002; **22**:97-101.

Bodin L, Verstuyft C, Tregouet DA et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. *Blood* 2005; **106**:135-140.

- Brockmüller J, Kirchheiner J, Meisel C et al. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. *Pharmacogenomics* 2000; **1**:125-151.
- C Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N Engl J Med* 1995; **333**:11-17.
- D Daly AK, King BP. Pharmacogenetics of oral anticoagulants. *Pharmacogenetics* 2003; **13**:247-252.
- Daly AK, King BP. Contribution of CYP2C9 to variability in vitamin K antagonist metabolites. *Expert Opin Drug Metab Toxicol* 2006; **2**:3-15.
- D' Andrea G, D' Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. *Blood* 2005; **105**:645-649.
- Dickmann LJ, Rettie AE, Kneller MB et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans (AA). *Mol Pharmacol* 2001; **60**:382-387.
- E Edelbroek PM, van Kempen GM, Hessing TJ et al. Analysis of phenprocoumon and its hydroxylated and conjugated metabolites in human urine by high-performance liquid chromatography after solid-phase extraction. *J Chromatogr* 1990; **530**:347-358.
- F Furuya H, Fernandez Salguero P, Gregory W et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. *Pharmacogenetics* 1995; **5**:389-392.

- G Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. *Pharmacogenetics* 1994; **4**:285-299.
- Gonzales FJ. Molecular genetics of the P450 superfamily. *Pharmacol Ther* 1990; **45**:1-38.
- Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. *J Bio Chem* 1992; **267**:83-90.
- H He M, Korzekwa KR, Jones JP et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. *Arch Biochem Biophys* 1999; **372**:16-28.
- Heimark LD, Toon S, Low LK et al. The mechanism of the warfarin-rifampin drug interaction in humans. *Clin Pharmacol Ther* 1987; **42**:388-394.
- Hermida J, Zarza J, Alberca I et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. *Blood* 2002; **99**:4237-4239.
- Higashi MK, Veenstra DL, Kondo LML et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *J Am Med Assoc* 2002; **287**:1690-1698.
- Hillman MA, Wilke RA, Caldwell MD et al. Relative impact of covariants in prescribing warfarin according to CYP2C9 genotype. *Pharmacogenetics* 2004; **14**:539-547.
- Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. *Chest* 2001; **119**:8S-21S.

- Hummers-Pradier E, Hess S, Adham IM et al. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. *Eur J Clin Pharmacol* 2003; **59**:213-219.
- I Ieiri I, Tainaka H, Morita T et al. Catalytic activity of three variants (Ile, Leu and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single strand conformation polymorphism analysis. *Ther Drug Monit* 2000; **22**:237-244.
- Ikawa M, Stahmann MA, Link KP. Studies on 4'-hydroxycoumarins v. the condensation of alpha, beta-unsaturated ketones with 4'-hydroxycoumarin. *J Am Chem Soc* 1944; **66**:902-906.
- Imani J, Ieiri I, Mamiya K et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. *Pharmacogenetics* 2000; **10**:85-89.
- Inoue K, Yamazaki H, Imiya K et al. Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methylhydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian population. *Pharmacogenetics* 1997; **7**:103-113.
- J Jacques LB. *Anticoagulant Therapy*. Thomas Springfield, IL 1965.
- K Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. *Pharmac Ther* 1997; **73**:67-74.
- Kammerer B, Kahlich R, Ufer M et al. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes. *Anal Bioanal Chem*. 2005; **383**:909-917.

Kidd RS, Straughn AB, Meyer MC et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. *Pharmacogenetics* 1999; **9**:71-80.

Kirchheiner J, Meineke I, Freytag G et al. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenase 1 and 2. *Clin Pharmacol Ther* 2002; **72**:62-75.

Kirchheiner J, Brockmöller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. *Clin Pharmacol Ther* 2002; **71**:286-269.

Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. *Eur J Clin Pharmacol* 1984; **26**:753-759.

L Lindh JD, Lundgren S, Holm L et al. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. *Clin Pharmacol Ther* 2005; **78**:540-550.

Li T, Chang CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. *Nature* 2004; **427**:541-544.

Loebstein R, Yonath H, Peleg D et al. Interindividual variability in sensitivity to warfarin-nature or nurture? *Clin Pharmacol Ther* 2001; **70**:159-164.

Loi C-M, Vestal RE. Drug metabolism in the elderly. *Pharmacol Ther* 1988; **36**:131-149.

Lubetsky A, Dekel-Stern E, Chetrit A et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. *Thromb Haemost* 1999; **81**:396-399.

- M Mahgoub A, Dring LG, Idle JR et al. Polymorphic hydroxylation of debrisoquine in man. *Lancet* 1977; **II**:584-586.
- Mamiya K, Ieiri I et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. *Epilepsia* 1998; **39**:1317-1329.
- Mannucci PM. Genetic control of anticoagulation. *Lancet* 1999; **353**:688-689.
- Margaglione M, Colaizzo D, D'Andrea G et al. Genetic modulation of oral anticoagulation with warfarin. *Thromb Haemost* 2000; **84**:775-758.
- Masche UP, Rentsch KM, von Felten A et al. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. *Eur J Clin Pharmacol* 1999; **54**:857-864.
- Mehann RR, Gosden JR, Rout D et al. Human cytochrome P450 PB-1: A multigene family involved in mephenytoin and steroid oxydations that maps to chromosome 10. *Am J Human Genet* 1988; **42**:26-37.
- Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in polymorphism in man. *Human drug metabolism. Br. J. Clin. Pharmacol* 1998; **45**:525-538.
- de Morais SMF, Wilkinson GR, Blaisdell J et al. Identification of a new genetic defect responsible for the polymorphism of (S)- mephenytoin metabolism in Japanese. *Mol Pharmacol* 1994; **46**:594-598.
- N Nebert DW. Polymorphism in drug-metabolizing enzymes: What is their clinical relevance and why do they exist? *Am J Hum Genet* 1997; **60**:279-290.

- Nelson DR, Koymans L, Kamatki T et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 1996; **6**:1-42.
- O Ogg MS, Brennan P, Meade T et al. CYP2C9*3 allelic variant and bleeding complications [Comment]. *Lancet* 1999; **354**:1124.
- O' Malley K, Stevenson ICH, Ward CA et al. Determinants of anticoagulant control in patients receiving warfarin. *Br J Clin Pharmacol* 1977; **4**:309-314.
- P Peyvandi F, Spreafico M, Siboni SM et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. *Clin Pharmacol Ther* 2004; **75**:198-203.
- R Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. *Pharmacotherapy* 2001; **21**:235-242.
- Rentsch KM, Guttec-Amsler U, Buhner R et al. Sensitive stereospecific determination of acenocoumarol and phenprocoumon in plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 2000; **742**:131-142.
- Rettie AE, Korzewska KR, Kunze KL et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug. *Chem Res Toxicol* 1992; **5**:54-59.
- Rettie AE, Wienkers LC, Gonzalez FJ et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. *Pharmacogenetics* 1994; **4**:39-42.

Romkes M, Faletto MB, Blaisdell JA et al. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450C subfamily. *Biochemistry* 1991; **30**:3247-3255.

Rostami-Hodjegan A, Nurminen S, Jackson PR et al. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. *Pharmacogenetics* 1996; **6**:121-149.

S Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. *Clin Pharmacol Ther* 2002; **72**:702-710.

Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in humans. *Diabetes* 1979; **28**:41-51.

Schalekamp T, Oosterhof M, van Meegen E et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. *Clin Pharmacol Ther* 2004; **5**:409-417.

Schalekamp T, Brasse BP, Roijers JF et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. *Clin Pharmacol Ther* 2006; **80**:13-22.

Shimada T, Yamazaki H, Mimura M et al. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogenes and toxic chemicals. Studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 1994; **270**:414-423.

Shon JH, Yoon YR, Kim KA et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. *Pharmacogenetics* 2002; **12**:111-119.

Spigset O, Hagg S, Soderstrom E et al. The paraxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? *Pharmacogenetics* 1999; **9**:409-417.

Steffensen FH, Kristensen K, Ejlersen E et al. Major hemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. *J Intern Med* 1997; **242**:497-503.

Steward DJ, Haining RL, Henne KR et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. *Pharmacogenetics* 1997; **7**:361-367.

Strom AR, Bradford LD, Rettie AE et al. Allele frequency of new CYP2C9 allele (CYP2C9*4) in Caucasians and African Americans (AA). *Drug Metab Rev* 2000; **32**:137-140.

Stubbins MJ, Harries LW, Smith G et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. *Pharmacogenetics* 1996; **6**:429-439.

Sullivan-Klose TH, Ghanayem BI, Bell DA et al. The role of the CYP2C9- Leu359 allelic variant in the tolbutamide polymorphism. *Pharmacogenetics* 1996; **6**:341-349.

T Tabrizi AR, Zehnbaauer BA, Borecki IB et al. The frequency and effects of cytochrome P450 /CYP 2C9 polymorphisms in patients receiving warfarin. *J Am Coll Surg* 2002; **194**:267-273.

Takahashi H, Kashima T et al. Comparison between in vitro and in vivo metabolism of (S)-warfarin catalytic activities of c-DNA express CYP2C9, and its Leu359 variant and their mixture versus unbound clearance in patients with corresponding CYP2C9 genotypes. *Pharmacogenetics* 1998; **8**:365-373.

Takahashi H, Sato T, Shimoyama Y et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. *Clin Pharmacol Ther* 1999; **66**:569-581.

Takahashi H, Echizen H. Pharmacogenetics of warfarin. Elimination and its clinical implications. *Clin Pharmacokinet* 2001; **40**:587-603.

Takahashi H, Wilkinson GR, Caraco Y et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. *Clin Pharmacol Ther* 2003; **73**:253-263.

Tassies D, Freire C, Pijoan J et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. *Haematologica* 2002 ; **87**:1185-1191.

Taube J, Halsall D, Baglin T. Influence of cytochrome P-450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. *Blood* 2000; **96**:1816-1819.

Thijssen HH, Hamulyak K, Willigers H. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship. *Thromb Haemost* 1988; **60**:35-38.

Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. *Drug Metab Dispos* 2000; **28**:1284-1290.

Thijssen HH, Verkooijen IW, Frank HL. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. *Pharmacogenetics* 2000; **10**:757-760.

Thijssen HH, Driittij MJ, Vervoort LM et al. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. *Clin Pharmacol Ther* 2001; **70**:292-298.

Thijssen HH, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. *Clin Pharmacol Ther* 2003; **74**:61-68.

Toon S, Heimark LD, Trager WF et al. Metabolic fate of phenprocoumon in humans. *J Pharmaceut Sci* 1985; **74**:1037-1040.

Toon S, Low LK, Gibaldi M, et al. The warfarin-sufinpyrazone interaction: stereochemical considerations. *Clin Pharmacol Ther* 1986; **39**:15-24.

U Ufer M, Svensson J, Krausz K et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. *Europ J Clin Pharmacol* 2004; **809**:217-26.

Ufer M, Kammmerer B, Kahlich R et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. *Xenobiotica* 2004; **34**:847-59.

Ufer M. Comparative pharmacokinetics of vitamin k antagonists : warfarin, phenprocoumon and acenocoumarol. *Clin Pharmacokinet* 2005; **44**:1227-1246.

V Van der Weide J, Steijns L, van Weelden M et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. *Pharmacogenetics* 2001; **11**:287-291.

Verstuyft C, Morin S, Robert A et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. *Pharmacogenetics* 2001; **11**:735-737.

Visser L, van Vliet M, van Schaik R et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. *Pharmacogenetics* 2004; **14**:27-33.

- de Vries JX, Simon M, Volker U et al. Comparative plasma disposition and anticoagulant activities of racemic phenprocoumon and its metabolites in rats. *Haemostasis* 1993; **23**:13-18.
- de Vries JX, Schmitz-Kummer ES. Determination of the coumarin anticoagulant phenprocoumon and metabolites in human plasma, urine and breast milk by high-performance liquid chromatography after solid-phase extraction. *J Chromatogr B Biomed Appl* 1994; **655**:63-71.
- W Wang S-L, Huang J-D, Lai M-D et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. *Pharmacogenetics* 1995; **5**:37-42.
- Wedlund PJ. The CYP2C19 enzyme polymorphism. *Pharmacology* 2000; **61**:174-183.
- Wells PS, Holbrook AM, Crowther NR et al. Interactions of warfarin with drugs and food. *Ann Intern Med* 1994; **121**:676-683.
- Wheeler C, Trager WF, Porter WR: Stereochemical aspects of the metabolism of phenprocoumon in rat liver microsomes. *Biochem Pharmacol* 1981; **30**:1785-1790.
- Wienkers LC, Wurden CJ, Storch E et al. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. *Drug Metab Dispos* 1996; **24**:610-614.
- Y Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. *Biochem Pharmacol* 1997; **54**:1195-1203.
- Yamazaki H, Inoue K, Chiba K et al. Comparative studies of the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin,

flurbiprofen, and diclofenac by human liver microsomes. *Biochem Pharmacol* 1998; **56**:243-251.

Yasar U, Tybring G, Hildestrand M et al. Role of CYP2C9 polymorphism in losartan oxidation. *Drug Metab Dispos* 2001; **29**:1051-1056

Yasar U, Lundgren S, Eliasson E et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. *Biochemical and Biophysical Research Communication* 2002; **299**:25-28.

- Z Zarza J, Hermida J, Montes R et al. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in Spanish population. *Blood* 2002; **100**:734.

Weitere:

Fachinformation Marcumar, Firma La-Roche

Internet:

<http://www.drnelson.utmen.edu/CytochromeP450.html>

<http://www.imm.ki.se/CYPalleles>